Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insilico Medicine
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
While artificial intelligence has proven its value in drug discovery, for most companies, the power of their AI systems is only as strong as the data those systems are trained on. However, stakeholders – from individual companies to consortiums and service vendors -- are finding creative approaches to overcome the so-called data problem and strengthen their AI models.
- Artificial Intelligence
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.